This site is intended for healthcare professionals
Hidradenitis suppurativa (HS) Learning Zone
Declaration of sponsorship Novartis Pharma AG

HS Treatment

Declaration of sponsorship Novartis Pharma AG
Read time: 75 mins
Last updated:16th Sep 2021
Published:16th Sep 2021

Discover how timely and efficacious treatment of hidradenitis suppurativa (HS) is needed to minimise the immense burden of the disease. Also learn about: 

  • The unmet needs for patients with hidradenitis suppurativa in our interview with Dr Joslyn Kirby
  • Treatment goals and treatment options available for hidradenitis suppurativa patients
  • The future of hidradenitis suppurativa treatment in our overview of clinical trials

Unmet needs in HS

Join Dr Joslyn Kirby below to gain an overview of the unmet needs for patients with hidradenitis suppurativa.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

HS treatment goals

Explore the treatment goals of hidradenitis suppurativa with Dr Joslyn Kirby, including the reduction of symptoms and long-term control.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Treatment options for HS

Find out the treatment options that are currently available to reduce symptoms, relieve pain, and prevent infection with Dr Joslyn Kirby.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Future treatments for moderate-to-severe HS

Get to know the novel treatments currently being investigated that leverage the evolving understanding of hidradenitis suppurativa pathophysiology with Dr Joslyn Kirby.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Santos-Pérez MI, García-Rodicio S, del Olmo-Revuelto MA, Pozo-Román T. Ustekinumab for Hidradenitis Suppurativa: A Case Report. Actas Dermo-Sifiliográficas (English Ed. 2014;105(7):720–722.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: